Previous close | 5.10 |
Open | 5.10 |
Bid | 0.00 |
Ask | 0.00 |
Strike | 10.00 |
Expiry date | 2024-12-20 |
Day's range | 5.10 - 5.10 |
Contract range | N/A |
Volume | |
Open interest | N/A |
– Four unique ICD-10-PCS codes, effective October 1, 2024, for replacement of arteries in the upper and lower extremities using Humacyte’s HAV – – BLA submission under Priority Review by FDA for the treatment of vascular trauma, supported by Phase 2/3 clinical trial results and real-world use treating wartime trauma injuries in Ukraine – DURHAM, N.C., June 17, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantabl
Key Insights Humacyte to hold its Annual General Meeting on 11th of June Salary of US$603.8k is part of CEO Laura...
On May 31, 2024, Heather Prichard, Chief Operating Officer of Humacyte Inc (NASDAQ:HUMA), sold 191,511 shares of the company, according to the SEC Filing.